文献速递痛风与晶体性关节病

DNA甲基化特征区分痛风与无症状高尿酸血症并在免疫代谢位点与遗传风险汇聚

DNA methylation signatures distinguish gout from asymptomatic hyperuricaemia and converge with genetic risk at immune-metabolic loci.
PubMed 文献 · Ann Rheum Dis · 2026-09-29

本研究为两阶段病例对照表观遗传学研究,发现外周血DNA甲基化可在痛风、无症状高尿酸血症和正常尿酸对照间区分阶段特异性差异,且差异甲基化区域富集于痛风/血尿酸风险位点及转录因子结合位点。结论支持甲基化用于分子分层,但需前瞻性验证。

要点

  • 外周血DNA甲基化可区分痛风、无症状高尿酸血症与正常尿酸状态。
  • 差异甲基化区域富集于HLA-DRB1、TAP2、GNAS等痛风/尿酸风险位点。
  • 甲基化联合临床变量将痛风vs无症状高尿酸血症的AUC从0.67提升至0.87。

核心结论

  • 外周血DNA甲基化捕获了痛风、高尿酸血症和正常尿酸状态间可重复的阶段特异性差异,并与免疫代谢遗传风险汇聚。
  • 这些特征支持基于甲基化的分子分层,但临床部署前需前瞻性验证。

研究设计与样本

  • 两阶段病例对照表观遗传学研究,纳入痛风124例、无症状高尿酸血症121例和正常尿酸对照124例。
  • 发现队列83例采用全基因组靶向亚硫酸氢盐测序分析外周血DNA甲基化。
  • 独立验证队列286例采用靶向扩增子甲基化测序验证候选特征。
  • 采用LASSO logistic回归构建仅甲基化及表观遗传-临床分类器。

主要发现

  • 痛风、高尿酸血症和正常尿酸对照的所有3组两两比较均识别出差异甲基化区域,映射至84个与痛风/血尿酸风险位点重叠的基因,包括HLA-DRB1、TAP2和GNAS。
  • 差异甲基化区域富集于转录因子结合位点,ZNF571与IL27和SAA2相关联。
  • 仅甲基化模型区分痛风与正常尿酸对照的测试集AUC为0.96。
  • 甲基化模型在痛风vs非痛风对照中优于临床变量(AUC 0.91 vs 0.78;DeLong P=0.032)。

关键数值与推荐

  • 仅甲基化模型区分痛风与正常尿酸对照的测试集AUC为0.96。
  • 甲基化模型在痛风vs非痛风对照中AUC为0.91,临床变量为0.78(DeLong P=0.032)。
  • 甲基化联合临床变量区分痛风vs无症状高尿酸血症的AUC从0.67提升至0.87(DeLong P=0.018)。
  • 差异甲基化区域映射至84个与痛风/血尿酸风险位点重叠的基因。

临床怎么用

  • 外周血DNA甲基化特征有望辅助区分痛风与无症状高尿酸血症,弥补临床变量在两者鉴别中的不足。
  • 甲基化分类器在区分痛风与非痛风对照时表现优于临床变量,可作为分子分层工具。
  • 当前证据尚不支持临床常规部署,需前瞻性验证后使用。

局限性

  • 研究为病例对照设计,需前瞻性验证后方可临床部署。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Why only a minority of hyperuricaemic individuals develop gout remains unclear, and epigenetic differences between these states are poorly characterised. We aimed to define DNA methylation signatures distinguishing gout from asymptomatic hyperuricaemia and evaluate their utility for molecular stratification. METHODS: We conducted a 2-stage case-control epigenetic study of gout (n = 124), asymptomatic hyperuricaemia (n = 121), and normouricaemic controls (n = 124). Peripheral-blood DNA methylation was profiled by genome-wide targeted bisulphite sequencing in a discovery cohort (n = 83), integrating differentially methylated regions (DMRs) and cytosines (DMCs) with genome-wide association study loci and transcription-factor binding sites (TFBSs). Candidate signatures were then tested by targeted amplicon methylation sequencing in an independent cohort (n = 286), and least absolute shrinkage and selection operator logistic regression constructed methylation-only and epigenetic-clinical classifiers. RESULTS: DMRs were identified across all 3 pairwise comparisons of gout, hyperuricaemia, and normouricaemic controls, mapping to 84 genes that overlapped gout/serum urate risk loci-including HLA-DRB1, TAP2, and GNAS-and were enriched at TFBSs, with ZNF571 linked to IL27 and SAA2. One hundred thirteen DMCs were validated and used to build classifiers: a methylation-only model distinguished gout from normouricaemic controls (test-set area under the curve 0.96) and outperformed clinical variables in gout vs nongout controls (0.91 vs 0.78; DeLong P = 0.032), while integrating methylation with clinical variables improved the most challenging distinction-gout vs asymptomatic hyperuricaemia-from 0.67 to 0.87 (DeLong P = 0.018). CONCLUSIONS: Peripheral-blood DNA methylation captures reproducible, stage-specific differences across gout, hyperuricaemia, and normouricaemic states converging with immune-metabolic genetic risk. These signatures support methylation-based molecular stratification, although prospective validation is needed before clinical deployment.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Chen Z, Ren H, Ji X, et al. DNA methylation signatures distinguish gout from asymptomatic hyperuricaemia and converge with genetic risk at immune-metabolic loci. Ann Rheum Dis. 2026. PMID: 42810907. doi:10.1016/j.ard.2026.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。